Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENHANCE-I: DWP16001 Add-on Therapy in Type 2 Diabetes
NCT05466643Phase 3Recruiting
- Sponsor
- Daewoong Pharmaceutical
- Start
- Mar 2023
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of enavogliflozin in type 2 diabetes mellitus (T2DM), sponsored by Daewoong Pharmaceutical. Primary endpoint: Changes from Baseline HbA1c at 24 weeks. Started Mar 2023; status: recruiting.
02
Drugs
enavogliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05466643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05466643.